STOCK TITAN

Quantum-Si Reports Third Quarter 2024 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Quantum-Si (QSI) reported Q3 2024 financial results with revenue of $787,000 and gross margin of 47%. The company experienced sales pipeline acceleration but noted lengthening sales cycles, making it unlikely to achieve the full-year revenue guidance of $3.7-4.2 million. Operating expenses were $28.5 million, with a net loss of $25.3 million. Cash position stands at $196.3 million, providing runway into H2 2026. New library preparation and barcoding kits remain on track for Q4 launch. The company appointed Todd Bennett as CCO, highlighting improved commercial execution despite market challenges.

Quantum-Si (QSI) ha riportato i risultati finanziari del terzo trimestre 2024, con ricavi di $787,000 e un margine lordo del 47%. L'azienda ha registrato un'accelerazione nel pipeline di vendita, ma ha notato l'allungamento dei cicli di vendita, rendendo improbabile il raggiungimento della previsione di ricavi per l'intero anno di $3.7-4.2 milioni. Le spese operative sono state di $28.5 milioni, con una perdita netta di $25.3 milioni. La posizione di cassa si attesta a $196.3 milioni, garantendo un margine di manovra fino al secondo semestre del 2026. I nuovi kit di preparazione delle librerie e di codifica rimangono programmati per il lancio nel quarto trimestre. L'azienda ha nominato Todd Bennett come CCO, evidenziando un miglioramento nell'esecuzione commerciale nonostante le sfide di mercato.

Quantum-Si (QSI) reportó los resultados financieros del tercer trimestre de 2024, con ingresos de $787,000 y un margen bruto del 47%. La empresa experimentó una aceleración en el pipeline de ventas, pero notó que los ciclos de venta se están alargando, lo que hace poco probable alcanzar la guía de ingresos del año completo de $3.7-4.2 millones. Los gastos operativos fueron de $28.5 millones, con una pérdida neta de $25.3 millones. La posición de efectivo se sitúa en $196.3 millones, proporcionando margen hasta la segunda mitad de 2026. Los nuevos kits de preparación de bibliotecas y codificación siguen según lo previsto para su lanzamiento en el cuarto trimestre. La empresa nombró a Todd Bennett como CCO, destacando una mejora en la ejecución comercial a pesar de los desafíos del mercado.

Quantum-Si (QSI)는 2024년 3분기 재무 결과를 보고하며, 수익이 $787,000, 총 마진이 47%임을 밝혔다. 회사는 판매 파이프라인이 가속화되었지만, 판매 주기가 길어지고 있어 연간 수익 목표인 $3.7-4.2백만 달러를 달성할 가능성이 낮다고 언급했습니다. 운영 비용은 $28.5백만 달러였으며, 순손실은 $25.3백만 달러에 달합니다. 현금 보유액은 $196.3백만으로 2026년 하반기까지의 운영 자금을 보장합니다. 새로운 라이브러리 준비 및 바코딩 키트는 4분기 출시를 위해 예정대로 진행 중입니다. 회사는 Todd Bennett를 CCO로 임명하여 시장의 도전에도 불구하고 상업적 실행이 향상되었음을 강조했습니다.

Quantum-Si (QSI) a rapporté les résultats financiers du troisième trimestre 2024, avec un chiffre d'affaires de $787,000 et une marge brute de 47%. L'entreprise a connu une accélération de son pipeline de ventes, mais a noté que les cycles de vente s'allongent, rendant peu probable l'atteinte des prévisions de revenus annuels de $3.7-4.2 millions. Les frais d'exploitation se sont élevés à $28.5 millions, avec une perte nette de $25.3 millions. La position de trésorerie s'élève à $196.3 millions, offrant une marge de manœuvre jusqu'au deuxième semestre 2026. De nouveaux kits de préparation de bibliothèques et de codage restent sur la bonne voie pour un lancement au quatrième trimestre. L'entreprise a nommé Todd Bennett en tant que CCO, soulignant une meilleure exécution commerciale malgré les défis du marché.

Quantum-Si (QSI) berichtete über die finanziellen Ergebnisse des dritten Quartals 2024, mit einem Umsatz von $787,000 und einer Bruttomarge von 47%. Das Unternehmen erlebte eine Beschleunigung des Verkaufspipelines, stellte jedoch fest, dass sich die Verkaufszyklen verlängern, was es unwahrscheinlich macht, die jährliche Umsatzprognose von $3.7-4.2 Millionen zu erreichen. Die Betriebskosten betrugen $28.5 Millionen, mit einem Nettoverlust von $25.3 Millionen. Die Liquiditätsposition liegt bei $196.3 Millionen, was einen Spielraum bis ins zweite Halbjahr 2026 bietet. Neue Bibliotheksvorbereitung und Etikettierungskits sind weiterhin auf Kurs für den Launch im vierten Quartal. Das Unternehmen ernannte Todd Bennett zum CCO und hob die verbesserte kommerzielle Umsetzung trotz der Marktherausforderungen hervor.

Positive
  • Gross margin of 47% in Q3 2024
  • Strong cash position of $196.3 million providing runway into H2 2026
  • Successful reduction in year-to-date adjusted operating expenses while funding commercialization
  • Accelerating sales pipeline under new CCO leadership
Negative
  • Unlikely to meet full-year revenue guidance of $3.7-4.2 million
  • Q3 2024 net loss of $25.3 million
  • Lengthening sales cycles observed in Q3
  • Operating expenses increased to $28.5 million from $27.3 million year-over-year

Insights

The Q3 results reveal concerning trends. Revenue of $787,000 and gross margin of 47% show the company is still in early commercialization stages. The guidance reduction from $3.7-4.2M to an unspecified lower range signals execution challenges. While cash position remains strong at $196.3M, providing runway into H2 2026, the $25.3M quarterly net loss and negative $24.5M adjusted EBITDA indicate significant cash burn.

Operating expenses increased to $28.5M vs $27.3M YoY despite cost reduction efforts. The lengthening sales cycle and guidance miss raise questions about market adoption pace, though pipeline acceleration and new product launches could provide future catalysts.

The proteomics market entry shows mixed signals. While securing the first CRO customer demonstrates market expansion, the extended sales cycles align with broader life sciences tools sector challenges. The upcoming product launches of library preparation and barcoding kits could enhance market penetration, but current adoption metrics suggest a slower ramp than initially projected.

The integration with Liberate Bio for gene therapy applications highlights potential market diversification, though meaningful revenue impact likely remains distant. The 47% gross margin indicates pricing power but needs improvement for sustainable commercialization.

Sales Pipeline is Accelerating and New Kits Remain on Track for Q4 Launch

BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the third quarter ended September 30, 2024.

Press Release Highlights

  • Reported revenue of $787,000 for the third quarter of 2024
  • Announced that Liberate Bio has integrated Platinum® Next-Generation Sequencing into their platform for developing novel gene therapies with improved targeting capabilities
  • Announced appointments of industry veteran Todd Bennett as Chief Commercial Officer (“CCO”), John Vieceli, Ph.D. as Chief Product Officer and Lindsay Thompson as Chief Human Resources Officer
  • Highlighted Platinum-based advances in proteomic analysis presented at Human Proteome Organization World Congress 2024 in Dresden, Germany
  • Highlighted a manuscript from researchers at the University of Virginia published on BioRxiv highlighting Platinum’s capability to discriminate peptide variants at single amino acid resolution
  • New library preparation kit and barcoding kit remain on track for launch before year end
  • Highlighted the Company’s upcoming Investor Day on Wednesday, November 20, 2024, beginning at 10:00 a.m. ET

“We are pleased to see continued adoption of Platinum across multiple market segments, including academic research, pharma/biotech and most recently, adoption by our first customer from the contract research organization market. Under the leadership of our new CCO, there has been clear improvement in commercial execution and the overall acceleration of our sales pipeline,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “Even with this acceleration, we, like others in the tools space, have observed some lengthening of the sales cycle in the third quarter, making it likely that we will not achieve our full year guided revenue range of $3.7 million to $4.2 million. We have clear strategies in place that we believe will allow us to get as close to the guidance range as possible and despite the potential short fall, we remain very confident in the long-term commercial opportunity for Platinum and the growth of the proteomics market in general. We are excited for the future and believe that we will continue to deliver solid quarter over quarter growth as we move forward.”

Hawkins continued, “In addition, we continue to execute on our innovation roadmap and are on track to deliver two new kits by end of the year, which we believe will continue to drive broader market adoption. We are looking forward to revealing more details on our exciting technology roadmap and expanding commercial opportunities at our upcoming Investor Day on November 20th.”

Third Quarter 2024 Financial Results

For the third quarter of 2024, the Company recorded revenue of $787,000. Gross profit was $367,000 and gross margin was 47%. For the nine months ended September 30, 2024, the Company recorded revenue of $1.9 million, gross profit of $990,000, and gross margin of 53%. The periodic gross margin rate is expected to be variable in the near term as the Company works through the initial stages of commercialization as well as the timing and mix of product sales between instruments and consumable kits.

Total operating expenses were $28.5 million in the third quarter of 2024, compared to $27.3 million for the same period in the prior year, and $78.9 million for the nine months ended September 30, 2024, compared to $83.6 million for the same period in the prior year. Adjusted total operating expenses were $26.0 million in the third quarter of 2024 compared to $23.9 million for the same period in the prior year, and adjusted total operating expenses for the nine months ended September 30, 2024 were $72.3 million compared to $72.6 million for the same period in the prior year. The Company has successfully reduced overall adjusted operating expenses on a year to date basis while funding the ramp up in commercialization efforts. This reduction was driven by the Company’s 2023 R&D realignment initiative to streamline and focus R&D efforts on delivering product enhancements to customers. Overall, the Company has been able to reduce core areas of spend while accelerating R&D focus, efficiency, and delivery while still funding the Company’s full commercial launch of its Platinum® instrument.

Net loss was $25.3 million in the third quarter of 2024, compared to a net loss of $24.7 million in the same period of the prior year, and a net loss of $67.9 million for the nine months ended September 30, 2024, compared to a net loss of $73.9 million for the same period in the prior year. Adjusted EBITDA was negative $24.5 million in the third quarter of 2024, compared to negative $22.6 million in the same period of the prior year, and negative $67.7 million for the nine months ended September 30, 2024, compared to negative $69.2 million for the same period in the prior year. A reconciliation of the non-GAAP financial measures adjusted total operating expenses and adjusted EBITDA is provided in a table included in this press release.

As of September 30, 2024, the Company’s cash and cash equivalents and investments in marketable securities were $196.3 million.

Financial Guidance

The Company provided updated full year 2024 financial guidance for adjusted operating expenses and cash usage as follows:

Adjusted total operating expenses

Approximately $100 million

Total cash usage

Approximately $92 million

The Company also updated its expectation that the balance in cash and cash equivalents and investments in marketable securities of $196.3 million as of September 30, 2024 will provide a runway into the second half of 2026.

Webcast and Conference Call Information

Quantum-Si will host a conference call to discuss its third quarter 2024 financial results on Tuesday, November 12, 2024, at 8:00 a.m. Eastern Time. Individuals interested in listening to the conference call may do so by joining the live webcast in the Investors section of the Quantum-Si website under Events & Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event.

Investor Day

The Company will host an Investor Day on Wednesday, November 20th beginning at 10:00 a.m. ET. To access the event, a live audio webcast will be available on the Investors section of the Company’s website.

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

Use of Non-GAAP Financial Measures

This press release presents the non-GAAP financial measures “adjusted total operating expenses” and “adjusted EBITDA.” The most directly comparable measures for these non-GAAP financial measures are total operating expenses and net loss. The Company has included below adjusted total operating expenses, which presents the Company’s total operating expenses after excluding goodwill impairment, stock-based compensation and restructuring costs. In addition, adjusted EBITDA further excludes interest, taxes, depreciation, amortization, dividend income, unrealized and realized gains and losses on marketable securities, changes in fair value of warrant liabilities and other income or expense.

A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding the Company’s financial condition and results of operations is included as Exhibit 99.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2024.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

QUANTUM-SI INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and par value amounts)

(unaudited)

 

 

September 30,
2024

 

December 31,
2023

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

42,268

 

 

$

133,860

 

Marketable securities

 

154,076

 

 

 

123,876

 

Accounts receivable, net of allowance of $0 and $0, respectively

 

1,022

 

 

 

368

 

Inventory

 

4,091

 

 

 

3,945

 

Prepaid expenses and other current assets

 

4,371

 

 

 

4,261

 

Total current assets

 

205,828

 

 

 

266,310

 

Property and equipment, net

 

16,254

 

 

 

16,275

 

Internally developed software, net

 

 

 

 

532

 

Operating lease right-of-use assets

 

13,677

 

 

 

14,438

 

Other assets

 

695

 

 

 

695

 

Total assets

$

236,454

 

 

$

298,250

 

Liabilities and stockholders’ equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

2,153

 

 

$

1,766

 

Accrued payroll and payroll-related costs

 

4,603

 

 

 

4,943

 

Accrued contracted services

 

2,133

 

 

 

1,519

 

Accrued expenses and other current liabilities

 

2,839

 

 

 

1,815

 

Current portion of operating lease liabilities

 

3,614

 

 

 

1,566

 

Total current liabilities

 

15,342

 

 

 

11,609

 

Warrant liabilities

 

357

 

 

 

1,274

 

Operating lease liabilities

 

10,211

 

 

 

13,737

 

Other long-term liabilities

 

24

 

 

 

11

 

Total liabilities

 

25,934

 

 

 

26,631

 

 

 

 

 

Stockholders’ equity

 

 

 

Class A Common stock, $0.0001 par value; 600,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 122,775,352 and 121,832,417 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively

 

12

 

 

 

12

 

Class B Common stock, $0.0001 par value; 27,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 19,937,500 shares issued and outstanding as of September 30, 2024 and December 31, 2023

 

2

 

 

 

2

 

Additional paid-in capital

 

773,873

 

 

 

767,239

 

Accumulated other comprehensive loss

 

153

 

 

 

-

 

Accumulated deficit

 

(563,520

)

 

 

(495,634

)

Total stockholders’ equity

 

210,520

 

 

 

271,619

 

Total liabilities and stockholders’ equity

$

236,454

 

 

$

298,250

 

QUANTUM-SI INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except per share amounts)

(unaudited)

 

 

Three months ended
September 30,

 

Nine months ended
September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Revenue:

 

 

 

 

 

 

 

Product

$

764

 

 

$

216

 

 

$

1,776

 

 

$

654

 

Service

 

23

 

 

 

7

 

 

 

90

 

 

 

28

 

Total revenue

 

787

 

 

 

223

 

 

 

1,866

 

 

 

682

 

 

 

 

 

 

 

 

 

Cost of revenue

 

420

 

 

 

115

 

 

 

876

 

 

 

372

 

 

 

 

 

 

 

 

 

Gross profit

 

367

 

 

 

108

 

 

 

990

 

 

 

310

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

 

16,171

 

 

 

16,587

 

 

 

42,653

 

 

 

50,588

 

Selling, general and administrative

 

12,284

 

 

 

10,696

 

 

 

36,236

 

 

 

33,010

 

Total operating expenses

 

28,455

 

 

 

27,283

 

 

 

78,889

 

 

 

83,598

 

Loss from operations

 

(28,088

)

 

 

(27,175

)

 

 

(77,899

)

 

 

(83,288

)

Dividend and interest income

 

2,688

 

 

 

2,572

 

 

 

9,149

 

 

 

7,274

 

Unrealized gain on trading securities

 

 

 

 

1,953

 

 

 

 

 

 

8,302

 

Realized loss on trading securities

 

 

 

 

(1,901

)

 

 

 

 

 

(6,489

)

Change in fair value of warrant liabilities

 

121

 

 

 

(162

)

 

 

917

 

 

 

(81

)

Other income (expense), net

 

9

 

 

 

(15

)

 

 

(10

)

 

 

370

 

Loss before provision for income taxes

 

(25,270

)

 

 

(24,728

)

 

 

(67,843

)

 

 

(73,912

)

Provision for income taxes

 

(43

)

 

 

 

 

 

(43

)

 

 

 

Net loss

$

(25,313

)

 

$

(24,728

)

 

$

(67,886

)

 

$

(73,912

)

 

 

 

 

 

 

 

 

Net loss per common share attributable to common stockholders, basic and diluted

$

(0.18

)

 

$

(0.17

)

 

$

(0.48

)

 

$

(0.52

)

Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted

 

142,399

 

 

 

141,660

 

 

 

142,039

 

 

 

141,154

 

 

 

 

 

 

 

 

 

Other comprehensive gain (loss):

 

 

 

 

 

 

 

Net unrealized gain on marketable securities, net of tax

$

163

 

 

$

 

 

$

163

 

 

$

 

Foreign currency translation adjustment

 

(3

)

 

 

 

 

 

(10

)

 

 

 

Total other comprehensive gain, net of tax

 

160

 

 

 

 

 

 

153

 

 

 

 

Comprehensive loss

$

(25,153

)

 

$

(24,728

)

 

$

(67,733

)

 

$

(73,912

)

QUANTUM-SI INCORPORATED

RECONCILIATION OF U.S. GAAP TO NON-GAAP FINANCIAL MEASURES

(in thousands)

(unaudited)

 

 

Three months ended
September 30,

 

Nine months ended
September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Net loss

$

(25,313

)

 

$

(24,728

)

 

$

(67,886

)

 

$

(73,912

)

Adjustments to reconcile to EBITDA:

 

 

 

 

 

 

 

Dividend and interest income

 

(2,688

)

 

 

(2,572

)

 

 

(9,149

)

 

 

(7,274

)

Depreciation and amortization

 

1,158

 

 

 

1,170

 

 

 

3,606

 

 

 

3,063

 

Income tax provision

 

43

 

 

 

 

 

 

43

 

 

 

 

EBITDA

 

(26,800

)

 

 

(26,130

)

 

 

(73,386

)

 

 

(78,123

)

Adjustments to reconcile to Adjusted EBITDA:

 

 

 

 

 

 

 

Unrealized gain on trading securities

 

 

 

 

(1,953

)

 

 

 

 

 

(8,302

)

Realized loss on trading securities

 

 

 

 

1,901

 

 

 

 

 

 

6,489

 

Change in fair value of warrant liabilities

 

(121

)

 

 

162

 

 

 

(917

)

 

 

81

 

Other (income) expense, net

 

(9

)

 

 

15

 

 

 

10

 

 

 

(370

)

Stock-based compensation

 

2,394

 

 

 

1,141

 

 

 

6,403

 

 

 

6,914

 

Restructuring costs

 

23

 

 

 

2,251

 

 

 

197

 

 

 

4,131

 

Adjusted EBITDA

$

(24,513

)

 

$

(22,613

)

 

$

(67,693

)

 

$

(69,180

)

 

Three months ended
September 30,

 

Nine months ended
September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Total operating expenses

$

28,455

 

 

$

27,283

 

 

$

78,889

 

 

$

83,598

 

Adjustments to reconcile to Adjusted total operating expenses:

 

 

 

 

 

 

 

Stock-based compensation

 

(2,394

)

 

 

(1,141

)

 

 

(6,403

)

 

 

(6,914

)

Restructuring costs

 

(23

)

 

 

(2,251

)

 

 

(197

)

 

 

(4,131

)

Adjusted total operating expenses

$

26,038

 

 

$

23,891

 

 

$

72,289

 

 

$

72,553

 

 

Investor Contact:

Doug Farrell

VP, Investor Relations

ir@quantum-si.com

Media Contact:

Katherine Atkinson

SVP, Commercial Marketing

media@quantum-si.com

Source: Quantum-Si Incorporated

FAQ

What was Quantum-Si's (QSI) revenue in Q3 2024?

Quantum-Si reported revenue of $787,000 in Q3 2024.

What is Quantum-Si's (QSI) cash runway projection as of Q3 2024?

QSI's cash position of $196.3 million is expected to provide runway into the second half of 2026.

Will Quantum-Si (QSI) meet its 2024 revenue guidance?

The company indicated it is unlikely to achieve its full-year 2024 revenue guidance range of $3.7-4.2 million due to lengthening sales cycles.

What new products is Quantum-Si (QSI) launching in Q4 2024?

QSI plans to launch new library preparation and barcoding kits before the end of 2024.

Quantum-Si Incorporated

NASDAQ:QSI

QSI Rankings

QSI Latest News

QSI Stock Data

190.76M
97.95M
19.85%
36.12%
4.15%
Medical Devices
Measuring & Controlling Devices, Nec
Link
United States of America
BRANFORD